VENUS REMEDIES LTD. - 526953 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Venus Remedies'' R3SET takes strategic lap into wellness with holistic health Innovations.20-12-2023
20-12-2023
VENUS REMEDIES LTD. - 526953 - Three New Marketing Authorizations For Enoxaparin From Bahrain.
Venus Remedies limited has successfully obtained new market authorizations for Enoxaparin from Bahrain.18-12-2023
VENUS REMEDIES LTD. - 526953 - Update Under Reg 30(LODR)
Fine imposed on Venus Remedies Limited by NSE & BSE for omission to submit a single page containing standalone profit and loss statement for the period ended on 30th September 2023 due to inadvertent scanning error.15-12-2023
VENUS REMEDIES LTD. - 526953 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Stop Transfer intimation under regulation 39(3) of LODR.07-12-2023
VENUS REMEDIES LTD. - 526953 - Venus Remedies Granted Market Authorizations For Enoxaparin In Azerbaijan.
Venus Remedies granted Market Authorization for Enoxaparin in Azerbaijan.05-12-2023
Venus Remedies receives market authorisations in Saudi Arabia and Philippines
Venus Remedies shares stood at 386.25on the BSE, down by 0.35%, at the closing hours on Friday.03-12-2023
VENUS REMEDIES LTD. - 526953 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Venus Remedies Limited granted Market Authorisations in Saudi Arabia and Philippines01-12-2023
VENUS REMEDIES LTD. - 526953 - Unaudited Financial Results For The Quarter Ended On 30Th Sep 2023.
Unaudited Financial results for the quarter ended on 30th Sep 2023.25-11-2023
VENUS REMEDIES LTD. - 526953 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper publication of UFR as on 30th Sep 2023.11-11-2023
VENUS REMEDIES LTD. - 526953 - Submission Of Unaudited Financial Results For The Period Ended On 30Th September 2023.
Unaudited Financial Results as on 30th Sep 2023.09-11-2023